Treatment Protocols in Age-related Macular Degeneration and Diabetic Retinopathy: An Age of Discovery

0.75 CME
$0 FEE
Treatment Protocols in Age-related Macular Degeneration and Diabetic Retinopathy: An Age of Discovery


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Activity Description

The integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies into treatment protocols for patients with retinal disease provides for enhanced visual acuity outcomes and the potential to delay disease progression. As treatment protocols for diabetic retinopathy (DR) and neovascular age-related macular degeneration (nAMD) continue to be evaluated and refined, questions remain pertaining to optimizing treatment dosing for the long-term benefit and management of patients with DR and nAMD. In this educational activity, experts in the field evaluate the latest evidence for the optimization of treatment dosing and management of patients with DR as well as differentiate injection protocols that have the potential to enhance long-term benefits in the treatment of nAMD.

Target Audience

The intended audience for this activity is ophthalmologists, retina specialists, and other health care professionals involved in the management of patients with age-related macular degeneration and diabetic retinopathy.

Learning Objective(s)

Upon successful completion of this activity, participants should be better able to:

  • Evaluate new evidence pertaining to the optimization of treatment dosing and management of patients with diabetic retinopathy.
  • Differentiate injection protocols in terms of their ability to optimize the long-term benefits of anti-vascular endothelial growth factor therapy in the treatment of neovascular age-related macular degeneration.


Darius M. Moshfeghi, MD
Chief, Retina Division
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA


Andrew A. Moshfeghi, MD, MBA
Director, Vitreoretinal Surgery and Medical Retina Fellowships
Director, Clinical Trials Unit
Associate Professor of Ophthalmology
USC Roski Eye Institute
Keck School of Medicine
University of Southern California
Los Angeles, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 30, 2020, through January 29, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Moderator and Faculty report the following relationship(s)

Andrew A. Moshfeghi, MD, MBA
Consulting Fee: Alimera, Allegro, Allergan, Bausch + Lomb, Clearside, EyePoint, Genentech, Graybug, Novartis, Pr3vent, Regeneron, Visunex
Speakers Bureau: Allergan
Contracted Research: Genentech, Regeneron
Ownership Interest: OptiSTENT, Pr3vent, Visunex

Darius M. Moshfeghi, MD
Intellectual Property/Patent: dSentz, Linc, Pr3vent, Promisight, Versl
Consulting Fee: Bayer, Congruence Medical, Iconic Therapeutics, Novartis, Regeneron, Visunex
Ownership Interest: dSentz, Grand Legend Technologies, Linc, Pr3vent, Promisight, Pykus, Versl, Visunex
Scientific Advisory Board: Akebia, Pykus
Steering Committee: Bayer, Iconic Therapeutics, Regeneron

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at